BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cancer death in the United States, and also one of the major cancer-related deaths in Chinese. Androgen deprivation therapy (ADT) is the first line treatment for metastatic PCa. PCa ultimately relapses with subsequent ADT treatment failure and becomes castrate-resistant (CR). It is important to develop effective therapies with a surrogate marker towards CR PCa. METHOD: Histone deacetylase (HDAC) inhibitors were examined to determine their effects in androgen receptor (AR)/ cellular prostatic acid phosphatase (cPAcP)-positive PCa cells, including LNCaP C-33, C-81, C4-2 and C4-2B and MDA PCa2b androgen-sensitive and androgen-independent cells, ...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostat...
Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resist...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDA...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
<p>The androgen receptor (AR) signaling axis is a well-established therapeutic target in prostate ca...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most pati...
Prostate cancer (PCa) is the most common malignancy in American males. If diagnosed in early stages,...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Prostate cancer (PCa) is the most frequent cancer in men above the age of 50 years. Despite radical ...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostat...
Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resist...
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading ...
Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDA...
We identified the molecular target by histone deacetylase (HDAC) inhibitors for exploring their pote...
<p>The androgen receptor (AR) signaling axis is a well-established therapeutic target in prostate ca...
Historically, androgen-deprivation therapy has been the cornerstone for treatment of metastatic pros...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Prostate cancer (PCa) is the second most common cancer affecting men worldwide. PCa shows a broad-sp...
Histone deacetylase inhibitors (HDACIs) are showing promise as therapeutic agents for hematological ...
The number of males diagnosed with prostate cancer (PCa) is increasing all over the world. Most pati...
Prostate cancer (PCa) is the most common malignancy in American males. If diagnosed in early stages,...
Human prostatic acid phosphatase (PAcP) is a 100 kDa glycoprotein composed of two subunits. Recent a...
Prostate cancer (PCa) is the most frequent cancer in men above the age of 50 years. Despite radical ...
Earlier we identified PPP2CA, which encodes for the a-isoform of protein phosphatase 2A (PP2A) catal...
Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostat...
Prostate cancer (PCa) is the second most common malignancy among men in the world. Castration-resist...